Abstract：
The prognostic value of microRNA-140-5p (miR-140-5p) expression in cancer patients has been investigated, but with inconsistent results. This meta-analysis aims to determine the prognostic significance of miR-140-5p expression in patients with various malignancies. A comprehensive literature search was conducted using PubMed, Web of Science, ProQuest, Cochrane, and Google Scholar to identify relevant studies published before June 2023. Pooled hazard ratios (HR) and odds ratios (OR) with 95 % confidence intervals (CI) were calculated to assess the prognostic importance and clinicopathological features of miR-140-5p in overall survival (OS) and disease-free survival (DFS) of cancer patients, respectively. The CancerMIRNome database and other OS analysis webservers were utilized to explore the prognostic value and expression profile of miR-140-5p. A total of 17 studies were included in the final analysis. The results demonstrated that decreased miR-140-5p expression was significantly associated with inferior OS (pooled HR 0.63; 95 % CI, 0.51-0.79; p < 0.001) and DFS (pooled HR 0.40; 95 % CI, 0.25-0.64; p < 0.001). Pooled ORs indicated a significant correlation between reduced miR-140-5p expression and positive lymph node metastasis (LNM; OR = 3.42; 95 % CI, 2.36-4.94; p < 0.001), advanced tumor stage (OR = 2.80; 95 % CI, 2.07-3.78; p < 0.001), and positive distant metastasis (DM; OR = 10.81; 95 % CI, 3.31-35.30; p < 0.001). No significant associations were observed between miR-140-5p expression and gender (OR = 0.94; 95 % CI, 0.70-1.28; p = 0.70), age (OR = 1.31; 95 % CI, 0.99-1.74; p = 0.06), tumor size (OR = 1.55; 95 % CI, 0.77-3.10; p = 0.22), and histological grade (OR = 1.20; 95 % CI, 0.46-3.10; p = 0.71). Subgroup analyses revealed that decreased miR-140-5p expression was associated with shorter OS in subgroups based on sample size (<100 or >100), tumor origin (GI or non-GI), and cancer type (GC/CRC). Bioinformatic analysis supported the finding that miR-140-5p was downregulated in most tumor tissues, and its reduced expression was linked to poor prognosis in patients with multiple malignancies. The prognostic significance of miR-140-5p in predicting reduced OS and DFS suggests that measuring miR-140-5p expression levels before treatment could serve as a valuable biomarker for identifying cancer patients with an unfavorable prognosis and improving clinical management.
摘要：
已经研究了microRNA-140-5p（miR-140-5p）表达在癌症患者中的预后价值，但结果不一致。这项荟萃分析旨在确定miR-140-5p表达在各种恶性肿瘤患者中的预后意义。使用PubMed进行了全面的文献检索，WebofScience,ProQuest,科克伦,和谷歌学者确定2023年6月之前发表的相关研究。计算风险比（HR）和比值比（OR）以及95％置信区间（CI），以评估miR-140-5p在癌症患者的总生存期（OS）和无病生存期（DFS）中的预后重要性和临床病理特征。分别。利用CancerMIRNome数据库和其他OS分析网络服务器来探索miR-140-5p的预后价值和表达谱。共有17项研究纳入最终分析。结果显示miR-140-5p表达降低与不良OS(合并HR0.63;95%CI,0.51-0.79;p<0.001)和DFS(合并HR0.40;95%CI,0.25-0.64;p<0.001)显著相关。合并的OR表明miR-140-5p表达降低与淋巴结转移阳性之间存在显着相关性（LNM;OR=3.42;95％CI，2.36-4.94;p<0.001），晚期肿瘤分期（OR=2.80；95%CI，2.07-3.78；p<0.001），远处转移阳性（DM；OR=10.81；95％CI，3.31-35.30；p<0.001）。miR-140-5p表达与性别之间没有显著关联(OR=0.94;95%CI,0.70-1.28;p=0.70)。年龄（OR=1.31；95%CI，0.99-1.74；p=0.06），肿瘤大小（OR=1.55；95%CI，0.77-3.10；p=0.22），和组织学分级（OR=1.20；95%CI，0.46-3.10；p=0.71）。亚组分析显示，基于样本量（<100或>100），在亚组中，降低的miR-140-5p表达与较短的OS相关。肿瘤起源（GI或非GI），和癌症类型（GC/CRC）。生物信息学分析支持miR-140-5p在大多数肿瘤组织中下调的发现，其表达降低与多种恶性肿瘤患者的不良预后有关。miR-140-5p在预测降低的OS和DFS中的预后意义表明，在治疗前测量miR-140-5p表达水平可以作为鉴定预后不良的癌症患者和改善临床管理的有价值的生物标志物。
